Press coverage about Henry Schein (NASDAQ:HSIC) has been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Henry Schein earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.2330036052665 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Henry Schein (NASDAQ:HSIC) traded down $1.62 on Tuesday, hitting $67.50. 2,754,500 shares of the stock traded hands, compared to its average volume of 1,169,812. Henry Schein has a 52 week low of $65.28 and a 52 week high of $93.50. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. The firm has a market capitalization of $10,850.00, a PE ratio of 19.39, a PEG ratio of 1.95 and a beta of 1.03.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.03). Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The firm had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter last year, the company earned $0.84 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. equities research analysts anticipate that Henry Schein will post 3.6 EPS for the current fiscal year.

Henry Schein announced that its board has authorized a stock buyback program on Monday, September 18th that permits the company to buyback $400.00 million in shares. This buyback authorization permits the company to repurchase up to 6.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Several brokerages recently commented on HSIC. Piper Jaffray Companies raised shares of Henry Schein from a “neutral” rating to an “overweight” rating in a research note on Friday, September 15th. Royal Bank Of Canada began coverage on shares of Henry Schein in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $91.00 price objective for the company. Zacks Investment Research downgraded shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. TheStreet downgraded shares of Henry Schein from a “b” rating to a “c+” rating in a research note on Monday, November 6th. Finally, Jefferies Group LLC decreased their price target on shares of Henry Schein from $89.00 to $74.00 and set a “hold” rating for the company in a research report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Henry Schein presently has an average rating of “Hold” and an average target price of $89.88.

COPYRIGHT VIOLATION WARNING: “Henry Schein (HSIC) Getting Somewhat Favorable News Coverage, Report Shows” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at

In other news, SVP Paul Rose sold 2,126 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the sale, the senior vice president now directly owns 17,841 shares in the company, valued at $3,077,750.91. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.19% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Insider Buying and Selling by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.